Latest Articles
Women Survivors of Colorectal Cancer Face Long-Term Sexual Health Challenges - Technology Networks
Women Survivors of Colorectal Cancer Face Long-Term Sexual Health Challenges Technology Networks
Published: June 4, 2025, 3:30 p.m.
Colorectal cancer leaves lasting toll on women’s sexual health - UBC News
Colorectal cancer leaves lasting toll on women’s sexual health UBC News
Published: June 4, 2025, 2:55 p.m.
Paula S. Cousins Ovarian & Endometrial Cancer Foundation, Inc. is this week’s winner of Loving Giving Local - yourerie.com
Paula S. Cousins Ovarian & Endometrial Cancer Foundation, Inc. is this week’s winner of Loving Giving Local yourerie.com
Published: June 4, 2025, 2:22 p.m.
Genmab advances with lower dose of Rina-S in endometrial cancer trials - Investing.com Canada
Genmab advances with lower dose of Rina-S in endometrial cancer trials Investing.com Canada
Published: June 3, 2025, 8:43 a.m.
Genmab advances with lower dose of Rina-S in endometrial cancer trials - Investing.com
Genmab advances with lower dose of Rina-S in endometrial cancer trials Investing.com
Published: June 3, 2025, 8:41 a.m.
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer - Insider Monkey
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer Insider Monkey
Published: June 3, 2025, 5 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo Finance
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo Finance
Published: June 2, 2025, 6:30 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - Yahoo
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial Yahoo
Published: June 2, 2025, 6:30 p.m.
Link copied to clipboard!